Affordable Access

Intravitreal Diclofenac for Refractory Uveitic Cystoid Macular Edema

Authors
Publisher
Ophthalmic Research Center
Publication Date
Keywords
  • Original Article

Abstract

Purpose To evaluate the effect of a single dose of intravitreal diclofenac on best- corrected visual acuity (BCVA) and central macular thickness (CMT) in patients with refractory uveitic cystoid macular edema (CME). Methods In this prospective non-comparative case series, 8 eyes of 8 patients with refractory CME secondary to chronic intermediate uveitis received a single intravitreal injection of diclofenac (500 µg/0.1ml) in addition to other systemic (oral prednisolone and methotraxate) and topical (betamethasone) remission maintaining drugs. Outcome measures were changes in BCVA and CMT after treatment. Results Mean BCVA remained relatively unchanged at 12, 24 and 36 weeks (0.69, 0.70 and 0.64 LogMAR, respectively) as compared to baseline (0.71 LogMAR). Mean CMT, however, decreased from 488 µm at baseline to 416 and 456 µm at 24 and 36 weeks, respectively. None of the changes were statistically significant. Conclusion In eyes with refractory uveitic CME, intravitreal injection of diclofenac insignificantly reduced CMT but this was not associated with visual improvement.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Intravitreal diclofenac for refractory uveitic cys...

on Journal of ophthalmic & vision... January 2013

[Uveitic cystoid macular edema: intravitreal triam...

on Klinische Monatsblätter für... January 2007

Intravitreal bevacizumab in refractory uveitic mac...

on European journal of ophthalmol... 2009

Intravitreal bevacizumab versus triamcinolone acet...

on Journal of ocular pharmacology... April 2010
More articles like this..